Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/69873
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Arastehfar, Amir | por |
dc.contributor.author | Carvalho, Agostinho | por |
dc.contributor.author | Nguyen, M. Hong | por |
dc.contributor.author | Hedayati, Mohammad Taghi | por |
dc.contributor.author | Netea, Mihai G. | por |
dc.contributor.author | Perlin, David S. | por |
dc.contributor.author | Hoenigl, Martin | por |
dc.date.accessioned | 2021-01-28T21:42:50Z | - |
dc.date.available | 2021-01-28T21:42:50Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Arastehfar, A.; Carvalho, A.; Nguyen, M.H.; Hedayati, M.T.; Netea, M.G.; Perlin, D.S.; Hoenigl, M. COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions? J. Fungi 2020, 6, 211. https://doi.org/10.3390/jof6040211 | por |
dc.identifier.uri | https://hdl.handle.net/1822/69873 | - |
dc.description.abstract | The recent global pandemic of COVID-19 has predisposed a relatively high number of patients to acute respiratory distress syndrome (ARDS), which carries a risk of developing super-infections. <i>Candida</i> species are major constituents of the human mycobiome and the main cause of invasive fungal infections, with a high mortality rate. Invasive yeast infections (IYIs) are increasingly recognized as s complication of severe COVID-19. Despite the marked immune dysregulation in COVID-19, no prominent defects have been reported in immune cells that are critically required for immunity to <i>Candida</i>. This suggests that relevant clinical factors, including prolonged ICU stays, central venous catheters, and broad-spectrum antibiotic use, may be key factors causing COVID-19 patients to develop IYIs. Although data on the comparative performance of diagnostic tools are often lacking in COVID-19 patients, a combination of serological and molecular techniques may present a promising option for the identification of IYIs. Clinical awareness and screening are needed, as IYIs are difficult to diagnose, particularly in the setting of severe COVID-19. Echinocandins and azoles are the primary antifungal used to treat IYIs, yet the therapeutic failures exerted by multidrug-resistant <i>Candida</i> spp. such as <i>C. auris</i> and <i>C. glabrata</i> call for the development of new antifungal drugs with novel mechanisms of action. | por |
dc.description.sponsorship | M.H. received research funding by Gilead and Pfizer. D.S.P. receives research support and/or serves on advisory boards for Amplyx, Cidara, Scynexis, N8 Medical, Merck, Regeneron, and Pfizer. He also has a patent covering the detection of fungal species and drug resistance, as well as a pending patent on COVID-19 detection licensed to T2 Biosystems. A.C. was supported by the Fundação para a Ciência e a Tecnologia (FCT) (CEECIND/03628/2017 and PTDC/MED-GEN/28778/2017). Additional support was provided by FCT (UIDB/50026/2020 and UIDP/50026/2020), the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement through the European Regional Development Fund (ERDF) (NORTE-01-0145-FEDER-000013 and NORTE-01-0145-FEDER-000023), the European Union’s Horizon 2020 research and innovation program under grant agreement no. 847507, and the “la Caixa” Foundation (ID 100010434) and FCT under the agreement LCF/PR/HP17/52190003. | por |
dc.language.iso | eng | por |
dc.publisher | Multidisciplinary Digital Publishing Institute | por |
dc.relation | CEECIND/03628/2017 | por |
dc.relation | PTDC/MED-GEN/28778/2017 | por |
dc.relation | UIDB/50026/2020 | por |
dc.relation | UIDP/50026/2020 | por |
dc.relation | info:eu-repo/grantAgreement/EC/H2020/847507/EU | por |
dc.rights | openAccess | por |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | por |
dc.subject | candidemia | por |
dc.subject | candiduria | por |
dc.subject | oral candidiasis | por |
dc.subject | mycobiome | por |
dc.subject | COVID-19 | por |
dc.title | COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions? | por |
dc.type | article | por |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | https://www.mdpi.com/2309-608X/6/4/211 | por |
oaire.citationStartPage | 1 | por |
oaire.citationEndPage | 13 | por |
oaire.citationIssue | 4 | por |
oaire.citationVolume | 6 | por |
dc.date.updated | 2021-01-08T14:44:18Z | - |
dc.identifier.eissn | 2309-608X | - |
dc.identifier.doi | 10.3390/jof6040211 | por |
dc.subject.fos | Ciências Médicas::Ciências da Saúde | por |
dc.subject.wos | Science & Technology | por |
sdum.journal | Journal of Fungi | por |
oaire.version | VoR | por |
Aparece nas coleções: | ICVS - Artigos em revistas internacionais / Papers in international journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
jof-06-00211.pdf | 263,2 kB | Adobe PDF | Ver/Abrir |
Este trabalho está licenciado sob uma Licença Creative Commons